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Abstract
Background: The availability of clinically valid biomarkers contribute to improve the diagnosis and clinical 
management of diseases. A valine-to-phenylalanine substitution at position 617 (V617F) in the Janus kinase 2 (JAK2) 
gene has been recently associated with key signaling abnormalities in the transduction of haemopoietic growth-factor 
receptors and is now considered as a useful clinical marker of myeloproliferative neoplasms. Several methods have 
recently been reported to detect the JAK2 V617F point mutation and show variable sensitivity.
Methods: Using the Luminex xMAP technology, we developed a quantitative assay to detect the JAK2V617F variant. 
The method was based on polymerase chain reaction (PCR) followed by hybridization to specific probes coupled with 
internally dyed microspheres. The assay comprises 3 steps: genomic DNA extraction, end point PCR reaction, direct 
hybridization of PCR fragments and quantification. It has been tested with different sources of nucleic acid.
Results: Applied to whole blood samples, this quantitative assay showed a limit of detection of 2%. A highly sensitive 
allele-specific primer extension reaction performed in parallel allowed to validate the results and to identify the 
specimens with values below 2%.
Conclusion: Direct hybridization assay using the Luminex xMAP technology allows sensitive quantification of 
JAK2V617F from blood spots. It is simple and can be easily performed in a clinical setting.
Background
Clonal dysregulation linked to myeloproliferative neo-
plasms (MPN) arising from acquired mutations in the
haematopoietic progenitor cells lead to a wide range of
clonal haematological malignant diseases including poly-
cythemia vera (PV), essential thrombocythemia (ET),
myeloid metaplasia with myelofibrosis (MMM), chronic
myelomonocytic leukemia (CMML), chronic myeloge-
nous leukemia (CML), hypereosinophilic syndrome
(HES), and systemic mast cell disease (SMCD)[1]. These
disorders have been studied at the molecular levels and
several of them have been associated with gene mutations
resulting in constitutive activation of protein tyrosine
kinases [2-4].
Jun activated kinase 2 (JAK2) is a cytoplasmic tyrosine
kinase with a key role in signal transduction from multi-
ple haemopoietic growth-factor receptors [5]. JAK2 is
activated upon the binding of type 1 cytokine ligands
including erythropoietin (EPO), granulocyte mac-
rophage-colony stimulating factor (GM-CSF), and
thrombopoietin (TPO) with its receptor. This results in
the production of red blood cells, granulocytes/mac-
rophages, and platelets, respectively. Recently, several
groups have reported a somatically acquired c.1849G>T
point mutation in exon 14 of JAK2 gene (JAK2V617F) [6].
This point mutation results in a Valine to Phenylalanine
change at position 617 in the JH2 pseudo-kinase domain
and may potentially be responsible for key signaling
abnormalities observed in several MPN, including PV, ET
and IMF [1,7-9]. This mutation generates a constitutively
active tyrosine kinase that confers growth factor indepen-
dence through the loss of autoinhibition leading to a con-
stitutive activation and uncontrolled proliferation of
haematopoietic cells [8]. The JAK2V617F variant is asso-
ciated with increase hemoglobin concentration, increase
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levels of white blood cells, splenomegaly, and increase
risk of leukemic transformation. Although detected at
very low levels in healthy donors [10], the reported preva-
lence of the JAK2V617F mutation in MPN is elevated:
90% in PV, 50% in ET or IMF and less then 20% in atypical
CML [6]. Complications linked to MPN include fibrosis,
hemorrhage, and thrombosis.
Several methods of detection with a wide range of sen-
sitivity have been published for the quantification of this
mutation. These methods include: direct sequencing (DS)
or RFLP, pyrosequencing, allele-specific primer extension
(ASPE), amplification-refractory mutation sequencing
(ARMS), quantitative real time PCR (QRT-PCR) and
DNA melting curve analysis [6,11-14]. The Luminex
xMAP technology allows simultaneous detection of up to
100 different analytes in a single reaction vessel [15]. This
technique is based on PCR reactions followed by direct
hybridization (DH) to probes coupled to internally dyed
microspheres. Several clinical applications of this flow
cytometry-based genotyping technique have been devel-
oped and are used for the detection of human pathogens,
HLA typing, multiplex screening of genetic diseases, gene
expression profiling, risk assessment, diagnosis or clinical
follow-up. In this study, we describe a simple quantitative
estimation of the JAK2V617F variant applied to whole




This project is part of a "health technology development
and assessment" program in molecular biology con-
ducted with the authorization and support of the Chi-
coutimi hospital and regional health authorities.
Genomic DNA was isolated from 20 mL of cultured HEL
92.1.7 cells (ATCC # TIB-180) grown in RPMI complete
growth medium using the QIAGEN blood and cell cul-
ture DNA kit 100/G (QIAGEN Inc. Canada). DNA con-
centration was measured by absorbance at 260 and 280
nm using a spectrophotometer. CEPH (Centre d'Étude du
Polymorphisme Humain) DNA was purchased from
Coriell Institute (Camden, New Jersey 08103, USA).
Genomic DNA was isolated from 2 mm punches of whole
blood specimens stored at room temperature on What-
man's FTA paper and processed as previously described
[16]. Briefly, a 2 mm punch was submerged in 100 μL of
methanol and allowed to evaporate overnight. The next
day, 25 μL of sterile water was added and the solution
incubated at 99°C for 10 min. Once cooled at room tem-
perature, the heating step was repeated and then the
tubes were spun at 3000 × g for 5 minutes. The superna-
tant containing the genomic DNA was transferred to a
clean tube and further used for amplification of the tar-
g e t ed  seq u e n c e  us i n g  a n  e n d  po i n t  PCR  as  w e l l  as  a n
allele-specific primer extension (ASPE) reaction.
Endpoint PCR and allele-specific primer extension 
reactions
The end point PCR reactions were carried out using 2.5
μL of FTA purified genomic DNA in a final volume of 25
μL containing: 1× NEB reaction buffer, 250 μM dNTPs,
0.3 μM of each PCR primers (Table 1) and 1 unit of Taq
DNA polymerase (New England Biolab, Canada). The
allele-specific primer extension (ASPE) reactions were
performed using a forward mutant-specific primer, a 3'
phosphate-blocked forward wild-type specific primer
and a reverse primer (Table 1). The amplification condi-
tions for both types of reactions were as follow: initial
denaturation at 95°C for 10 min followed by 45 cycles of
denaturation at 95°C for 30 sec, annealing at 60°C for 1
min and elongation at 72°C for 1 min. A final step at 72°C
for 5 min was added and samples were kept at 4°C until
used. All PCR reactions were performed on a Tgradient
thermocycleur (Montreal Biotech Inc, Canada). Ampli-
cons were visualized from a 2.0% agarose-gel electropho-
resis under standard conditions. DNA was quantified
using the Quant-iT Picogreen dsDNA reagent as
described by the manufacturer (Invitrogen, cat. #
P11496). The oligonucleotide primers were purchased
from Integrated DNA Technology Inc. (Coralville, IA).
Negative controls using sterile water were systematically
included in all amplification reactions.
Table 1: Primers and probes used in end point PCR, ASPE and DH reactions.
PCR Forward primer 5'-AGCAAGCTTTCTCACAAGCA-3'
Reverse primer 5'biotin-CTGACACCTAGCTGTGATCCTG-3'
DH Wild-type probe 5'unilinker-TGGAGTATGTGTCTGTGGAGA-3'
Mutant probe 5'unilinker-TGGAGTATGTTTCTGTGGAGA-3'
ASPE Forward primers 5'-AGCATTTGGTTTTAAATTATGGAGTATATT-3'
5'-AGCATTTGGTTTTAAATTATGGAGTATGTG-3'PO4
Reverse primer 5'biotin-CTGACACCTAGCTGTGATCCTG-3'
The reverse primer is biotinylated at its 5' end. The probes differing by a single nucleotide (bold letter) contain a unilinker at their 5' ends for 
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Coupling the oligonucleotide probes to the microspheres 
and optimization of the hybridization assays
The wild-type probe was coupled to the carboxylated
microspheres (xMAP; Luminex Corp., Austin, TX) bead
number 064 (Luminex product number L100-C164-01)
and mutated probe (Table 1) was coupled to the carboxy-
lated microspheres bead number 065 (Luminex product
number L100-C165-01) as described [17]. Each hybrid-
ization reaction comprised 2.5 μL of a 1 in 5 diluted PCR
products, 10 μL of TE buffer and 25 μL of 1.5× TMAC
buffer containing approximately 1500 of each micro-
spheres. The mixture was incubated at 95°C for 10 min-
utes followed by incubation at 53°C for 30 minutes. To
pellet the microspheres, the reactions were quickly spun
at 3000 × g for 5 min at room temperature. The superna-
tant was then removed and the microspheres resus-
pended in 75 μL of 1× TMAC hybridization buffer
containing 4 μg/mL streptavidin-R-phycoerythrin (Invit-
rogen cat. # S866). The plate was kept in the dark for 10
min and the beads were analyzed at room temperature
for assessment of the internal bead color and R-phyco-
erythrin reporter fluorescence on a Luminex 100 analyzer
with the following settings: 45 seconds-50 μL-100 beads.
The median fluorescence intensity (MFI) of at least 100
beads was computed for each bead set in the sample. The
probes with a unilinker at the 5'ends were purchased
from Integrated DNA Technology Inc. (Coralville, IA).
The optimal temperature of hybridization was estimated
by performing the hybridization at temperatures ranging
from 40°C up to 70°C. The effect of DNA concentration
on the kinetic of the hybridization reaction was evaluated
by testing 5 μL of the PCR products followed by dilutions
down to 1:128 and hybridizing at 53°C. The effect of time
on the kinetic of the hybridization reaction was deter-
mined by using 2.5 μL of PCR product and incubating at
53°C from 0 to 60 min.
Standard curve and quantitative detection of JAK2
The standard curves were generated using the wild-type
allele (CEPH DNA) PCR product and the mutated allele
(HEL DNA) PCR product diluted five fold and combined
together in order to generate a 0 to 100% range of the
wild-type to mutated allelic ratios. For the quantitative
detection of JAK2V617F, the specimens PCR products
were also diluted five fold and then hybridized to the cou-
pled microspheres as described above. The difference
between wild type and mutant probes median fluores-
cence intensity values were used to generate the standard
curve and specimen's profiles.
Results
Specimens, Primers and PCR
The initial step of our procedure was to choose the type
of genomic DNA and the DNA purification procedure for
our assay. To ensure confidentiality of the donor, an ali-
quot of 50 μL of fresh blood collected in EDTA-contain-
ing vaccutainer tubes was spotted onto an FTA card and
identified with a number prior to drying overnight. A sin-
gle FTA card could contain up to 5 specimens linked to
its code bar and was easily stored at room temperature in
the dark. A single 2 mm punch was sufficient to provide
enough genomic DNA for at least 8 genotyping assays.
An additional boiling step was added to the original pro-
cedure to improve the efficiency of genomic DNA recov-
ery. The amplification of the JAK2V617F targeted region
produced a single band of the expected size (155 bp) as
visualized from 2% agarose-gel electrophoresis stained
with ethidium bromide (not shown). Primers were
selected in regions with no known genetic variants pre-
venting the possibility of an allele drop out phenomenon
during amplification of the targeted region. To reach the
end point status, 45 cycles proved to be sufficient and safe
enough assuming 100% amplification efficiency for each
PCR cycle. All reactions reached the end point using the
procedure described above. Since the primers represent
the limiting factor in our PCR reactions, the amount of
DNA fragments generated during PCR was about 800 ng
which is in agreement with the amount of primers used.
Determination of the optimal kinetic parameters for direct 
hybridization
Following the amplification of the JAK2V617F targeted
region by PCR using control wild-type (CEPH, homozy-
gous wild-type) and homozygous mutated (HEL cells,
homozygous JAK2V617F/JAK2V617F mutant) genomic
DNA, we determined the hybridization temperature pro-
file of the wild-type and mutated probes coupled to their
corresponding microspheres (Fig. 1). The hybridization
temperature giving a good discrepancy between the wild-
type and mutated probes was about 53°C. We then tested
the effect of DNA concentration on the median fluores-
cence intensity (MFI) measured at that precise hybridiza-
tion temperature (Fig. 2). The MFI was directly
proportional to the DNA concentration for up to 5.0 μL
of undiluted PCR product. No reduction of the MFI was
observed at that concentration which sometimes
oc curr ed wit h l onge r  PCR  fra gm e n ts  (no t  s hown) .  W e
tested the effect of time on the kinetic of hybridization for
a maximum of 60 minutes (Fig. 3). When using 2.5 μL of
PCR products, the reactions reached a plateau after 30
minutes of incubation at 53°C for both the wild and
mutated types. No decrease in MFI was observed after 60
minutes of incubation.
Standard curve
In order to generate the standard curve, we combined
various amounts of wild-type and mutant PCR fragments
ranging from 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 70, 80, 90,Paradis et al. BMC Medical Genetics 2010, 11:54
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up to 100% mutant (Fig. 4). The differences between the
wild-type and mutated probes MFI values were plotted
on a polynomial graphic (Fig. 5A). The R2  values
remained above 0.99 confirming the quantitative nature
of our controls.
Quantitative and qualitative analysis of JAK2V617F 
variants
The quantitative detection of the JAK2 variants was per-
formed on specimens whole blood spotted onto FTA
cards as described above. The MFI values obtained
between the wild-type and mutated probes were sub-
tracted from one another and the differences were used
to generate a single bar graph (Fig. 5B). By comparing the
delta MFI values obtained from the specimens with those
of the standard curve (Fig. 5A), a percentage of mutant
allele to wild-type was assessable with an estimated limit
of detection of 2%. In order to increase the validity and
sensitivity of the test, we combined a qualitative ASPE
reaction to all specimens tested. All except one specimen
negative for JAK2V617F by direct hybridization were
negative by ASPE and all specimens positive for
JAK2V617F by direct hybridization were positive by
ASPE. In this typical example, specimens number 135
and 138 to 145 where given a negative results (absence of
the V617F variant) whereas specimens number 133, 134,
136, 137, 146, 147 and 148 where given a positive results
(presence of the V617F variant) with values of 35%, 47%,
3%, 90%, 62%, 55% and 55% mutant, respectively. Speci-
men 143 negative by DH and positive by ASPE was given
a value of bellow 2% mutant.
With a 45 cycles PCR reaction, the ASPE assay had a
higher sensitivity than the direct hybridization assay and
could theoretically detect 0.1% of mutated cells in a wild-
type background or 2 mutated alleles out of 2000 or 1 out
of 1000 cells. The ASPE reaction included a 3'phosphate-
blocked oligonucleotide corresponding to the wild-type
allele [18]. This allowed a reduction of the background
that sometime occurred from non-specific amplification
reaction. A good and reproducible concordance was
obtained between the direct hybridization reactions and
the ASPE assays (r = 0.95, p < 0.05). Specimens wild type
for the JAK2 alleles fluctuated slightly above the 0% stan-
Figure 1 Effect of temperature on the kinetic of hybridization. 
Panel A; homozygous wild type DNA, panel B: homozygous mutated 
DNA. Black bars correspond to the wild type probe (V617Fwt) and 
white bars correspond to mutated probe (V617Fmut). MFI: median flu-
orescent intensity.
Figure 2 Effect of the DNA concentration of the kinetic of hybrid-
ization. Panel A; homozygous wild type DNA, panel B: homozygous 
mutated DNA. Black bars correspond to the wild type probe (V617Fwt) 
and white bars correspond to mutated probe (V617Fmut). MFI: median 
fluorescent intensity.
Figure 3 Effect of time on the kinetic of hybridization. Panel A; ho-
mozygous wild type DNA, panel B: homozygous mutated DNA. Black 
bars correspond to the wild type probe (V617Fwt) and white bars cor-
respond to mutated probe (V617Fmut). MFI: median fluorescent inten-
sity.
Figure 4 Quantitative analysis of various ratios of wild type vs 
mutant alleles. Various ratios of wild type and mutated alleles ranging 
from 0% up to 100% mutated allele were analyzed using direct hybrid-
ization. Black bars correspond to the wild type probe (V617Fwt) and 
white bars correspond to mutated probe (V617Fmut). MFI: median flu-
orescent intensity.Paradis et al. BMC Medical Genetics 2010, 11:54
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dard control. The few that were positive by ASPE and
negative by DH were assigned a value bellow 2% mutant.
Discussion
Since the first reports in 2005 of the JAK2V617F variant,
numerous genotyping techniques have been developed.
Its detection has been included as a diagnostic criteria for
PV by the World Health Organization. Sensitivities vary
between 20% for DNA sequencing all the way down to
0.1% for ASPE. Some of them require exhaustive granulo-
cyte DNA purification steps which is time consuming
and sometimes difficult because monocytes, granulo-
cytes and platelets may aggregate [19]. In addition, a
recent study [20] suggests that platelets are better suited
for JAK2V617F mutation screening since granulocytes
analysis could lead to an underestimation of real carriers.
This is also supported by recent studies that detected the
JAK2V617F mutation in B- and T-lymphocytes [19] as
well as in NK-cells [21,22] making the use of whole blood
better suited then purified granulocytes, although this
mutation has not been found in any lymphoid malig-
nancy [6]. A recent study [23] comparing whole blood
and purified blood granulocytes identified a good corre-
lation between both sampling methods with allelic ratio
~15% higher on average for purified granulocytes. Using
only the data from blood cell counts and correcting for
the percentage of neutrophils, the percentage of mutated
JAK2V617F fitted perfectly the values obtained from
purified granulocytes.
In this study, we have developed and evaluated a quan-
titative assay for the detection of the JAK2V617F variant
in the Jun activated kinase 2 gene using the Luminex plat-
form. The Luminex technology offers two distinctive
approaches, either the xTAG protocol or the xMAP pro-
tocol. The former requires a DNA extraction, end point
PCR, an exo-sap treatment, an ASPE reaction followed by
an hybridization at 37°C. The later requires a DNA
extraction, an end point PCR followed by an hybridiza-
tion at a specific temperature, in this case, at 53°C.
Although the xMAP approach implies the predetermina-
tion of the optimal kinetic parameters, it requires less
steps to perform. The xMAP technology requires a cer-
tain level of experience and technical skills, but is simple,
sensitive and applicable at a reasonable cost. As starting
material, we choose whole blood spotted onto FTA cards
because of the genomic DNA stability, potential pathogen
inactivation and ease of storage of the specimens. The
methanol-water DNA extraction method proved to be
simple and highly reproducible allowing multiple geno-
typing assays from a single 2 mm punch. The end point
PCR amplification of the targeted region is straight for-
ward and easily assessed for efficiency by agarose-gel
electrophoresis.
We evaluated the possibility of using whole blood spot-
ted onto FTA cards to detect the JAK2V617F genetic
variant because of its numerous advantages including (1)
the simplicity of collection of blood sample, (2) room
temperature storage conditions without need for refriger-
ation, (3) pathogen inactivation that could be present in
human blood, (4) fast purification of DNA and (5) overall
low cost when compared to other DNA storage and puri-
fication methodologies. In addition, making use of the
methanol-water extraction protocol decreases substan-
tially the number of technical steps, time and costs asso-
ciated with human genomic DNA isolation that is
requires for PCR. In contrast, highly purified DNA is
required to perform real time PCR making this approach
more labor intensive and at increased costs. We believe
that FTA cards are therefore a good and inexpensive way
to store blood and test for the presence of the JAK2V617F
mutation.
A recent report [11] on the concordance of various
assays designed for the quantitative detection of
JAK2V617F concluded that the allelic burden as defined
by JAK2V617F/total JAK2 produced similar results with
variable sensitivity using a common set of standards. It
mentions the importance of using defined accurate stan-
dards for calibration. Our standards are composed of a
mixture of two PCR products eliminating the effect of
JAK2 gene copy number variation reported for the HEL
cell line. The PCR fragment produced by CEPH DNA
being 100% wild-type and the fragment produced by HEL
genomic DNA being 100% mutant, a mixture composed
of various amounts of both fragments generates stan-
dards that are simple to produce and can be directly com-
pared to the PCR fragments from the submitted
specimens. By comparison, later standards were com-
posed of various dilutions of UKE-1 cells (homozygous
mutant for JAK2V617F) and normal leukocytes (wild-
type JAK2). The linear profile of the standard curve from
the supplemental data does suggest that the values mea-
sured are accurate. We believe that both types of stan-
Figure 5 Polynomial graphic representation of the standard 
curve (A) and quantitative detection of JAK2V617F from speci-
mens (B). Typical representation of the delta MFI curves and bar 
graphs applied to the detection of JAK2V617F variant from specimens. 
The percentage of mutated alleles is determined by comparing the 
height of the bar graphs from specimens with the standard curve. The 
equation is Y = 0.0473X2-12.6X+256.Paradis et al. BMC Medical Genetics 2010, 11:54
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dards are accurate standards and the user may choose
which is more convenient depending on their laboratory
settings. We tested the 0%, 1%, 10%, 25%, 50%, 75% and
100% mutant control samples (kindly provided by S. Her-
mouet) and after appropriate dilutions, got values of 0%,
0%, 6%, 22%, 54%, 90% and 100%, respectively, which is a
good concordance between both types of standards (data
not shown). Our ASPE reaction gave 100% concordance
when these controls were tested for the presence or
absence of the mutated targeted sequence (not shown).
The ASPE reaction did detect the 1% control sample
whereas the Luminex DH assay did not which is in good
agreement with our estimated limit of detection of 2%.
Patients with more than 50% of mutated JAK2 allele can
harbor homozygote clones [22,24] and can carry wild-
type, heterozygous and homozygous clones making ques-
tionable the true meaning of a specific percentage value.
Some cells even carry multiple copies of the JAK2 gene
originating from genetic duplication and recombination.
The estimated percentages of JAK2V617F is therefore a
value that must not be considered as an actual number of
mutated cells compared to all nucleated cells in a sample
but rather a variable number of affected cells. Patients
with high percentage of JAK2V617F often carry the
mutation in a homozygous state that has a direct effect on
the true quantitative allele burden measured from whole
blood cells.
Using our end point PCR allows the production of a
single fragment for each specimen tested that should the-
oretically represent a constant final concentration assum-
ing that the end point is reached a few cycles before the
end of the amplification reactions. From the estimated
1000 genomes present in a single PCR reaction, we esti-
mated that 35 cycles is sufficient to reach the end point
assuming 100% amplification efficiency making 45 cycles
sufficient for our assay. The five-fold dilution of the spec-
imen PCR products prior to hybridization was imple-
mented because of the ease of making the standard curve
mixtures. This also allowed the use of the standard curve
samples for many more genotyping assays. Our assay has
the advantages of being simple, sensitive, and requires a
single PCR reaction.
Although at very low frequency, other mutations have
been reported in JAK2 exon 14 [25,26]. Those that are of
particular interest for us are located within the probes
targeted sequences and include C616Y and C618R. Theo-
retically, a compound heterozygous individual carrying
the V617F variant on one allele and either C616Y or
C618R on the other allele could not be detected unless
different probes were used.
We used a standard end point PCR reaction in parallel
with an ASPE reaction under identical amplification con-
ditions to validate our assays. During the PCR reaction,
both alleles are amplified using the same primers making
the amplification efficiency identical for both alleles and
consequently has little or no effect on the initial allelic
ratios as reported elsewhere [13]. Since both PCR and
ASPE reactions are ran under identical conditions and
products visualized by agarose-gel electrophoresis, the
results are easily comparable reinforcing the final diagno-
sis regarding the presence or absence of the JAK2V617F
variant especially for patients with values bellow 2%.
Direct hybridization of the Luminex xMAP technology
is a simple method taking advantage of the unique prop-
erties of DNA to form specific hybrids with its comple-
mentary sequences. Under specific hybridization
conditions such as temperature, DNA concentration, salt
concentration and time, one can discriminate two DNA
sequences having a single nucleotide polymorphism. To
our knowledge, this is the first report of a quantitative
detection of a mutated allele linked to a human disease
using this technology. We estimated our threshold of
detection to be 2% which is similar to most highly sensi-
tive detection technique reported to date. Furthermore,
patients with lower than 2% allele burden of the mutated
allele should not be considered positive as healthy patient
do carry this mutation at very low copies as previously
reported [14]. Increased sensitivity could also lead to false
positives.
Other mutations relevant to hematopoietic and myel-
oid malignancies have been reported [26] and may be
detectable by multiplexed PCR followed by our Luminex
assay, although the quantitative nature of multiplexing
and using direct hybridization is presently under investi-
gation. The next step would be to add other related muta-
tions to evaluate the possibility of multiplexing our
quantitative assay as other mutations in either exon 12, 13
and 15 of JAK2 [27,28] or other genes [26] linked to MPN
have recently been reported.
Conclusion
Direct hybridization assay using the Luminex xMAP
technology allows sensitive quantification of JAK2V617F
from blood spots. It is simple and can be easily performed
to support the diagnosis or clinical management of
myeloproliferative diseases.
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